Market Cap
€108.5b
Last Updated
2021/05/15 19:33 UTC
Data Sources
Company Financials +
Executive Summary
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Undervalued with excellent balance sheet and pays a dividend.
Similar Companies
Share Price & News
How has Sanofi's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SAN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: SAN's weekly volatility (2%) has been stable over the past year.
Market Performance
7 Day Return
1.5%
SAN
1.5%
FR Pharmaceuticals
-0.2%
FR Market
1 Year Return
-0.6%
SAN
1.8%
FR Pharmaceuticals
48.5%
FR Market
Return vs Industry: SAN underperformed the French Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: SAN underperformed the French Market which returned 48.4% over the past year.
Shareholder returns
| SAN | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 1.5% | -0.2% |
| 30 Day | 2.5% | 3.0% | 2.2% |
| 90 Day | 11.0% | 11.0% | 11.0% |
| 1 Year | 3.2%-0.6% | 5.5%1.8% | 52.4%48.5% |
| 3 Year | 46.4%30.5% | 36.0%22.8% | 26.1%15.2% |
| 5 Year | 47.9%21.8% | 48.7%23.9% | 78.3%55.2% |
Long-Term Price Volatility Vs. Market
How volatile is Sanofi's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
There's A Lot To Like About Sanofi's (EPA:SAN) Upcoming €3.20 Dividend1 month ago | Simply Wall St
If You Had Bought Sanofi (EPA:SAN) Stock Three Years Ago, You Could Pocket A 29% Gain Today1 month ago | Simply Wall St
Sanofi's (EPA:SAN) Intrinsic Value Is Potentially 87% Above Its Share PriceValuation
Is Sanofi undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SAN (€86.72) is trading below our estimate of fair value (€175.71)
Significantly Below Fair Value: SAN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SAN is good value based on its PE Ratio (8.9x) compared to the French Pharmaceuticals industry average (16.2x).
PE vs Market: SAN is good value based on its PE Ratio (8.9x) compared to the French market (24.5x).
Price to Earnings Growth Ratio
PEG Ratio: SAN is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: SAN is good value based on its PB Ratio (1.7x) compared to the FR Pharmaceuticals industry average (3.3x).
Future Growth
How is Sanofi forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
8.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SAN's forecast earnings growth (8.2% per year) is above the savings rate (0.4%).
Earnings vs Market: SAN's earnings (8.2% per year) are forecast to grow slower than the French market (19.3% per year).
High Growth Earnings: SAN's earnings are forecast to grow, but not significantly.
Revenue vs Market: SAN's revenue (4.2% per year) is forecast to grow slower than the French market (6.8% per year).
High Growth Revenue: SAN's revenue (4.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SAN's Return on Equity is forecast to be low in 3 years time (11.8%).
Past Performance
How has Sanofi performed over the past 5 years?
22.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAN has a large one-off gain of €6.3B impacting its March 31 2021 financial results.
Growing Profit Margin: SAN's current net profit margins (33%) are higher than last year (9%).
Past Earnings Growth Analysis
Earnings Trend: SAN's earnings have grown significantly by 22.3% per year over the past 5 years.
Accelerating Growth: SAN's earnings growth over the past year (253.2%) exceeds its 5-year average (22.3% per year).
Earnings vs Industry: SAN earnings growth over the past year (253.2%) exceeded the Pharmaceuticals industry 6.9%.
Return on Equity
High ROE: SAN's Return on Equity (19.4%) is considered low.
Financial Health
How is Sanofi's financial position?
Financial Position Analysis
Short Term Liabilities: SAN's short term assets (€33.8B) exceed its short term liabilities (€19.3B).
Long Term Liabilities: SAN's short term assets (€33.8B) exceed its long term liabilities (€32.1B).
Debt to Equity History and Analysis
Debt Level: SAN's debt to equity ratio (35.7%) is considered satisfactory.
Reducing Debt: SAN's debt to equity ratio has increased from 28.4% to 35.7% over the past 5 years.
Debt Coverage: SAN's debt is well covered by operating cash flow (33.1%).
Interest Coverage: SAN's interest payments on its debt are well covered by EBIT (18x coverage).
Balance Sheet
Dividend
What is Sanofi current dividend yield, its reliability and sustainability?
3.69%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SAN's dividend (3.69%) is higher than the bottom 25% of dividend payers in the French market (1.33%).
High Dividend: SAN's dividend (3.69%) is low compared to the top 25% of dividend payers in the French market (3.91%).
Stability and Growth of Payments
Stable Dividend: SAN's dividends per share have been stable in the past 10 years.
Growing Dividend: SAN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (32.9%), SAN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SAN's dividends in 3 years are forecast to be well covered by earnings (48.8% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
9.4yrs
Average management tenure
CEO
Paul Hudson (53 yo)
1.67yrs
Tenure
€11,341,612
Compensation
Mr. Paul Hudson serves as Chief Executive Officer and Director at Sanofi since September 1, 2019. Mr. Hudson was Chief Executive Officer of Novartis Pharmaceuticals at Novartis AG since July 1, 2016 until ...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD13.77M) is above average for companies of similar size in the French market ($USD3.92M).
Compensation vs Earnings: Paul's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: SAN's management team is seasoned and experienced (9.4 years average tenure).
Board Members
Experienced Board: SAN's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sanofi's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sanofi
- Ticker: SAN
- Exchange: ENXTPA
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €108.463b
- Shares outstanding: 1.25b
- Website: https://www.sanofi.com
Number of Employees
Location
- Sanofi
- 54, Rue La BoEtie
- Paris
- Ile-de-France
- 75008
- France
Listings
Biography
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/15 19:33 |
| End of Day Share Price | 2021/05/14 00:00 |
| Earnings | 2021/03/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.